Search results (63)
« Back to News & OpinionNews and Opinion from the Pandemic Sciences Institute at the University of Oxford
Media spotlight: PSI experts on Bundibugyo Ebola vaccines and treatments
28 May 2026
Several UK and global outlets have covered Oxford’s response to the Bundibugyo Ebola virus outbreak currently affecting the DRC and Uganda.
Statement on vaccine efforts relating to the Bundibugyo Ebolavirus outbreak in the DRC
22 May 2026
In response to the current Bundibugyo Ebolavirus outbreak in the Democratic Republic of the Congo, the Oxford Vaccine Group (OVG) is working urgently with Oxford’s own Clinical BioManufacturing Facility and the Serum Institute of India Pvt. Ltd. (SIIPL), to rapidly produce and scale doses of our ChAdOx-based monovalent Bundibugyo Ebolavirus candidate vaccine, ChAdOx1 BDBV.
UK launches a study of Andes hantavirus using a pre-approved outbreak protocol
21 May 2026
Study uses ISARIC's globally recognised Clinical Characterisation Protocol
Decentralising disease surveillance and modelling approaches will support equitable infectious disease responses
21 May 2026
By sharing data analytics instead of raw data, federated approaches enable surveillance and modelling while respecting ethical and legal boundaries.
Major European study warns current measures failing to halt spread of ‘superbugs’
14 May 2026
New data from 37 countries reveals the escalating threat of carbapenem-resistant K. pneumoniae and identifies ‘warning signals’ for E. coli, prompting calls for global genomic surveillance.
Improving early diagnosis of HIV and Hepatitis B and C with machine learning algorithms
12 May 2026
The BMC Infectious Diseases study is the first to investigate the integration of machine learning algorithms with primary care data to support testing for blood-borne diseases.
Media Spotlight: PSI experts comment on hantavirus outbreak
11 May 2026
PSI members have provided expert comment on the recent hantavirus outbreak across a range of media.
Epigames generate real-life insights to inform the future of pandemic preparedness
26 February 2026
Bringing together real environments and simulated outbreak scenarios, the epigames approach combines decision-making, real-time network dynamics and structured incentives.
Pandemic PACT launches new WHO Pandemic and Epidemic Intelligence Funding Tracker dashboard
17 February 2026
Pandemic and epidemic intelligence is essential for preventing, detecting and responding to current and future public health threats.
New review provides insights to inform future Nipah virus clinical trials
30 January 2026
The review, which has been published in The Lancet Microbe, addresses critical knowledge gaps, helping to inform the design of future clinical trials and improve patient treatment.
Ambitious research aiming to develop multivalent vaccines to protect against multiple deadly filoviruses
8 January 2026
Working with international partners, scientists across PSI and OVG will design and develop multivalent vaccine candidates with funding from CEPI and Horizon Europe.
Driving the development of new tools to combat Nipah virus outbreaks
18 December 2025
- Ethics, social science & humanities
- Nipah virus
- Pathogen biology & new threats
- Research news
- Vaccines, treatments, diagnostics & trials
PSI’s Nipah Virus Research Day, held on Wednesday, 19 November 2025, showcased promising developments, spanning new insights into Nipah virus biology, clinical trials of vaccines, the development of policy responses, and progress in developing diagnostics and treatments, all of which are helping improve responses to outbreaks of this deadly virus.
International collaboration launches largest-ever therapeutics trial for patients hospitalised with dengue
10 December 2025
A landmark international research collaboration has launched the largest clinical trial ever conducted to test therapeutics for moderate-severe dengue, a mosquito-borne viral disease that continues to spread rapidly driven by climate change and globalisation.
World's first Phase II Nipah virus vaccine trial launch
9 December 2025
The trial will assess the safety and immune response of the ChAdOx1 NipahB vaccine, developed by PSI scientists, in a region where the virus causes recurrent outbreaks.
First volunteer receives Lassa fever vaccine in cutting-edge Oxford trial
4 December 2025
The vaccine developed by PSI researchers aims to advance the fight against Lassa fever virus, a WHO priority pathogen posing a significant public health risk.
New analysis reveals major global gaps in genomic surveillance of antimicrobial resistance (AMR) – a call to action
24 November 2025
The analysis draws on data aggregated through the amr.watch platform, created by PSI's Centre for Genomic Pathogen Surveillance to build more equitable and effective genomic surveillance worldwide.
New research reveals optimal time intervals for COVID-19 vaccine boosters
1 September 2025
Two new papers from University of Oxford scientists have shown how the immune system reacts differently depending on the length of interval between vaccine doses.
New research published on maximising mpox vaccine availability
5 June 2025
Scientists have studied the immune response of a dose-sparing regimen to expand vaccine supply and protect more people from mpox.
Up to £16.5 million awarded to global consortium to overcome obstacles in infectious disease research
8 April 2025
The International Severe Acute Respiratory and emerging Infection Consortium (ISARIC) has been awarded up to £16.5 million to build on its globally-recognised efforts to prevent illness and deaths from epidemic-prone infectious diseases.
New science partnership to strengthen Africa’s pandemic resilience
27 March 2025
A groundbreaking research partnership is set to enhance Africa’s preparedness and response to future health crises.